Recently, we developed a complementary peptide targeting DKK3 (DKK3-CP) as a new anticancer substance and reported that DKK3-CP could significantly suppress cancer cell growth, migration, and invasion in OSCC-derived cells. This evidence concerns the gene DKK3 and cancer.